New immune drug takes on Hard-to-Treat cancers
NCT ID NCT07583316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will first find a safe dose, then test that dose in more patients to see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CRPA1A2 (a bispecific T cell engager)
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial, so the main goal is safety, not effectiveness. It is very small and may not work in larger groups. Side effects from T cell engagers can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can tailored nutrition boost recovery from head and neck surgery?